Table of Contents
Thrombosis
Volume 2012, Article ID 430460, 6 pages
http://dx.doi.org/10.1155/2012/430460
Review Article

Beneficial Effect of Ultra-Low-Dose Aspirin in Platelet Activity Alterations and Haemorrhage Observed in Experimental Portal Hypertension

Laboratoire d'Hématologie, UFR des Sciences Pharmaceutiques, Université de Bordeaux 2, Victor Segalen, 33076 Bordeaux Cedex, France

Received 15 June 2011; Accepted 29 August 2011

Academic Editor: Jawad Fareed

Copyright © 2012 F. X. Eizayaga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Garcia-Tsao and J. Bosch, “Management of varices and variceal hemorrhage in cirrhosis,” New England Journal of Medicine, vol. 362, no. 9, pp. 823–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Lisman, F. W. Leebeek, and P. G. de Groot, “Haemostatic abnormalities in patients with liver disease,” Journal of Hepatology, vol. 37, no. 2, pp. 280–287, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. D. P. Thomas, V. J. Ream, and R. K. Stuart, “Platelet aggregation in patients with Laennec's cirrhosis of the liver,” New England Journal of Medicine, vol. 276, no. 24, pp. 1344–1348, 1967. View at Google Scholar · View at Scopus
  4. D. P. Thomas, “Abnormalities of platelet aggregation in patients with alcoholic cirrhosis,” Annals of the New York Academy of Sciences, vol. 201, pp. 243–250, 1972. View at Google Scholar · View at Scopus
  5. A. Ordinas, S. Maragall, R. Castillo, and A. T. Nurden, “A glycoprotein I defect in the platelets of three patients with severe cirrhosis of the liver,” Thrombosis Research, vol. 13, no. 2, pp. 297–302, 1978. View at Google Scholar · View at Scopus
  6. G. Laffi, F. Cominelli, M. Ruggiero et al., “Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists,” Hepatology, vol. 8, no. 6, pp. 1620–1626, 1988. View at Google Scholar · View at Scopus
  7. G. Laffi, F. Marra, P. Failli et al., “Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides,” Gastroenterology, vol. 105, no. 1, pp. 148–156, 1993. View at Google Scholar · View at Scopus
  8. G. Laffi, F. Marra, P. Gresele et al., “Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation,” Gastroenterology, vol. 103, no. 2, pp. 641–646, 1992. View at Google Scholar · View at Scopus
  9. A. Ordinas, G. Escolar, I. Cirera et al., “Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions,” Hepatology, vol. 24, no. 5, pp. 1137–1142, 1996. View at Publisher · View at Google Scholar
  10. L. Albornoz, J. C. Bandi, J. C. Otaso, O. Laudanno, and R. Mastai, “Prolonged bleeding time in experimental cirrhosis: role of nitric oxide,” Journal of Hepatology, vol. 30, no. 3, pp. 456–460, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Vorobioff, J. E. Bredfeldt, and R. J. Groszmann, “Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension,” The American Journal of Physiology, vol. 244, no. 1, pp. G52–G57, 1983. View at Google Scholar · View at Scopus
  12. J. Kountouras, B. H. Billing, and P. J. Scheuer, “Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat,” British Journal of Experimental Pathology, vol. 65, no. 3, pp. 305–311, 1984. View at Google Scholar · View at Scopus
  13. C. Doutremepuich, O. Aguejouf, and P. Belon, “Effects of ultra-low-dose aspirin on embolization in a model of laser-induced thrombus formation,” Seminars in Thrombosis and Hemostasis, vol. 22, supplement 1, pp. 67–70, 1996. View at Google Scholar
  14. C. J. Smith, Y. Zhang, C. M. Koboldt et al., “Pharmacological analysis of cyclooxygenase-1 in inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 22, pp. 13313–13318, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Brenneis, T. J. Maier, R. Schmidt et al., “Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition,” FASEB Journal, vol. 20, no. 9, pp. 1352–1360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Barnett, J. Chow, D. Ives et al., “Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system,” Biochimica et Biophysica Acta, vol. 1209, no. 1, pp. 130–139, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. J. L. Masferrer, B. S. Zweifel, P. T. Manning et al., “Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3228–3232, 1994. View at Google Scholar · View at Scopus
  18. J. L. Johnson, J. Wimsatt, S. D. Buckel, R. D. Dyer, and K. R. Maddipati, “Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons,” Archives of Biochemistry and Biophysics, vol. 324, no. 1, pp. 26–34, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. F. X. Eizayaga, O. Aguejouf, P. Belon, and C. Doutremepuich, “Platelet aggregation in portal hypertension and its modification by ultra-low doses of aspirin,” Pathophysiology of Haemostasis and Thrombosis, vol. 34, no. 1, pp. 29–34, 2005. View at Publisher · View at Google Scholar
  20. P. A. Cahill, E. Redmond, and J. Sitzmann, “Endothelial dysfunction in cirrhosis and portal hypertension,” Pharmacology and Therapeutics, vol. 89, no. 3, pp. 273–293, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. F. X. Eizayaga, O. Aguejouf, V. Desplat, P. Belon, and C. Doutremepuich, “Modifications produced by indomethacin and L-NAME in the effect of ultralow-dose aspirin on platelet activity in portal hypertension,” Pathophysiology of Haemostasis and Thrombosis, vol. 35, no. 5, pp. 357–363, 2007. View at Publisher · View at Google Scholar
  22. D. Taubert, R. Berkels, N. Grosser, H. Schröder, D. Gründemann, and E. Schömig, “Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action,” British Journal of Pharmacology, vol. 143, no. 1, pp. 159–165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. F. X. Eizayaga, O. Aguejouf, V. Desplat, P. Belon, and C. Doutremepuich, “Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension,” World Journal of Gastroenterology, vol. 13, no. 38, pp. 5065–5070, 2007. View at Google Scholar · View at Scopus
  24. H. Segal, S. Cottam, D. Potter, and B. J. Hunt, “Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation,” Hepatology, vol. 25, no. 3, pp. 683–688, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Pihusch, A. Rank, P. Göhring, M. Pihusch, E. Hiller, and U. Beuers, “Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease,” Journal of Hepatology, vol. 37, no. 5, pp. 548–555, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Takeshita, H. Matsui, N. Shibata et al., “Earlier recurrence of esophageal varices, following therapy, in patients with primary biliary cirrhosis (PBC) compared with non-PBC patients,” Journal of Gastroenterology, vol. 39, no. 11, pp. 1085–1089, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Vlachogiannakos, J. Carpenter, J. Goulis, C. Triantos, D. Patch, and A. K. Burroughs, “Variceal bleeding in primary biliary cirrhosis patients: a subgroup with improved prognosis and a model to predict survival after first bleeding,” European Journal of Gastroenterology and Hepatology, vol. 21, no. 6, pp. 701–707, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Doutremepuich, O. Aguejouf, V. Desplat, and F. X. Eizayaga, “Aspirin therapy: an attempt to explain the events of prothrombotic complications after treatment discontinuation,” Thrombosis and Haemostasis, vol. 103, no. 1, pp. 171–180, 2010. View at Publisher · View at Google Scholar · View at Scopus